Drug: XS-03

Phase 2Biologic

NNovaOnco Therapeutics Co., Ltd.

Drug: XS-03 is one of 48 biologic programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerEnrolling by invitation

Metastatic Colorectal CancerPhase 2

Enrolling by invitation

Competition

Competitive Landscape

159 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 3

52 2

Keytruda

Merck & Co.

Phase 3

20 3

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

63 4

Opdivo

Bristol-Myers Squibb

Phase 3

13 5

Braftovi

Pfizer

Phase 3

12 6

Tecentriq

Roche

Phase 3

10 7

FOLFIRI

Amgen

Phase 3

38 8

Yervoy

Bristol-Myers Squibb

Phase 3

7 9

Lumakras

Amgen

Phase 3

2 10

Bayer Aspirin

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

Enrolling by invitation·NNovaOnco Therapeutics Co., Ltd.·Phase 1/2·NCT06936527·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: XS-03. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug: XS-03 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug: XS-03. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NovaOnco Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNovaOnco Therapeutics Co., Ltd.

Drug: XS-03

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News